Chemically Specific Analysis of OINDPs: Differentiation of Drug Particle Agglomeration by Raman Chemical Imaging

Share Button

Presented at: Respiratory Drug Delivery (RDD)  2014
 O Olkhovyk1,  Diem Ngo 2 and William Doub 2
1. Gateway Analytical,  5316 William Flynn Highway, Gibsonia, PA 15044
2. FDA/CDER/Division of Pharmaceutical Analysis, St. Louis , MO
Release Date: Monday, May 5, 2014

Drug Particle Agglomeration


Proper characterization of pharmaceutical products with respect to particle size and distribution requires that the extent and size of drug particle agglomerates is determined, as well as the size and number of primary Active Pharmaceutical Ingredients (API) particles. Such characterization may also be necessary for assessing product quality, establishing Bioequivalence (BE), evaluating out-of-specification issues, batch-to-batch comparison studies and addressing stability of the product during scale-up, and long-term shipping/storage in varying environmental conditions. By providing chemically specific identification for each particle in addition to Particle Size Distribution (PSD), Raman Chemical Imaging (RCI) is an effective tool for identifying whether observed aggregates/agglomerates are combinations of multiple primary API particles, API-excipient particles or multiple excipient particles. In concert with other particle sizing techniques, RCI analysis of agglomerates can benefit developers of Orally Inhaled and Nasal Drug Products (OINDPs), containing multiple APIs and/or excipients such as nasal suspensions, dry powder inhalers and metered dose inhalers.


Dr. Oksana Olkhovyk Ph.D., plays an important role supporting analytical testing services as the Senior Scientist at Gateway Analytical. She has over 15 years experience in Raman spectroscopy, imaging and material characterization. Dr. Olkhovyk has worked to support hundreds of projects as a scientific liaison between Gateway Analytical and their customers, as well as academic and industrial collaborators.

Leave a Reply